Abstract
BackgroundWe sought to identify an optimal oral corticosteroid regimen at the onset of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which would delay time to first relapse while minimising cumulative corticosteroid...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have